Literature DB >> 33363181

Acute and Chronic Sarcoid Arthropathies: Characteristics and Treatments From a Retrospective Nationwide French Study.

Carlotta Cacciatore1, Pierre Belnou2, Sara Thietart1, Carole Desthieux1, Mathilde Versini3, Noemie Abisror1, Sébastien Ottaviani4, Gregoire Cormier5, Alban Deroux6, Azeddine Dellal7, Nicolas Belhomme8, Nathalie Saidenberg Kermanac'H9,10, Philippe Khafagy11, Martin Michaud12, Sylvain Lanot13, Fabrice Carrat2,14, Olivier Fain1, Arsène Mékinian1.   

Abstract

Introduction: We aimed to analyze patients with acute and chronic joint involvements in sarcoidosis.
Methods: This is a retrospective multicenter analysis of patients with proven sarcoidosis, as defined by clinical, radiological, and histological criteria, with at least one clinical and/or ultrasonographic synovitis.
Results: Thirty-nine patients with sarcoid arthropathy were included, and among them 19 had acute sarcoidosis (Lofgren's syndrome). Joint involvement and DAS44-CRP were not significantly different in acute and chronic sarcoid arthropathies. Acute forms were more frequent than chronic sarcoid arthropathy in Caucasians, without any difference of sex or age between these 2 forms. Joint involvement was frequently more symmetrical in acute than chronic forms (100 vs. 70%; p < 0.05), with a more frequent involvement in wrists and ankles in acute forms, whereas the tender and swollen joint counts and the DAS44-CRP were similar between the 2 groups. Skin lesions were significantly more frequent in patients with acute forms [17 (89%) vs. 5 (25%); p < 0.05] and were erythema nodosum in all patients with Löfgren's syndrome and sarcoid skin lesions in those with chronic sarcoidosis. Among 20 patients with chronic sarcoidosis, treatment was used in 17 (85%) cases, and consisted in NSAIDs alone (n = 5; 25%), steroids alone (n = 5; 25%), hydroxychloroquine (n = 2; 20%), methotrexate (n = 3; 15%), and TNF inhibitors (n = 2; 10%). A complete/partial joint response was noted in 14 (70%) cases with a DAS44-CRP reduction of 2.07 [1.85-2.44] (from 3.13 [2.76-3.42] to 1.06 [0.9-1.17]; p < 0.05).
Conclusion: Sarcoid arthropathies have different clinical phenotypes in acute and chronic forms and various treatment regimens such as hydroxychloroquine and methotrexate could be used in chronic forms.
Copyright © 2020 Cacciatore, Belnou, Thietart, Desthieux, Versini, Abisror, Ottaviani, Cormier, Deroux, Dellal, Belhomme, Kermanac'H, Khafagy, Michaud, Lanot, Carrat, Fain and Mékinian.

Entities:  

Keywords:  infliximab; methotrexate; outcome; sarcoid arthropathy; sarcoidosis

Year:  2020        PMID: 33363181      PMCID: PMC7758528          DOI: 10.3389/fmed.2020.565420

Source DB:  PubMed          Journal:  Front Med (Lausanne)        ISSN: 2296-858X


  30 in total

1.  Sarcoid arthritis: clinical characteristics, diagnostic aspects, and risk factors.

Authors:  H Visser; K Vos; E Zanelli; W Verduyn; G M Th Schreuder; I Speyer; F C Breedveld; J M W Hazes
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

2.  Epidemiology of Sarcoidosis 1946-2013: A Population-Based Study.

Authors:  Patompong Ungprasert; Eva M Carmona; James P Utz; Jay H Ryu; Cynthia S Crowson; Eric L Matteson
Journal:  Mayo Clin Proc       Date:  2015-12-22       Impact factor: 7.616

Review 3.  Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1999-08       Impact factor: 21.405

Review 4.  Rheumatologic manifestations of sarcoidosis.

Authors:  Nadera J Sweiss; Karen Patterson; Ray Sawaqed; Umair Jabbar; Peter Korsten; Kyle Hogarth; Robert Wollman; Joe G N Garcia; Timothy B Niewold; Robert P Baughman
Journal:  Semin Respir Crit Care Med       Date:  2010-07-27       Impact factor: 3.119

Review 5.  Extrapulmonary manifestations of sarcoidosis.

Authors:  Deepak A Rao; Paul F Dellaripa
Journal:  Rheum Dis Clin North Am       Date:  2013-03-13       Impact factor: 2.670

Review 6.  Musculoskeletal and other extrapulmonary disorders in sarcoidosis.

Authors:  Hassane Awada; Ghada Abi-Karam; Fouad Fayad
Journal:  Best Pract Res Clin Rheumatol       Date:  2003-12       Impact factor: 4.098

Review 7.  Management of extrapulmonary sarcoidosis: challenges and solutions.

Authors:  Khalid Al-Kofahi; Peter Korsten; Christian Ascoli; Shanti Virupannavar; Mehdi Mirsaeidi; Ian Chang; Naim Qaqish; Lesley A Saketkoo; Robert P Baughman; Nadera J Sweiss
Journal:  Ther Clin Risk Manag       Date:  2016-11-07       Impact factor: 2.423

8.  Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-Part 1: definition and development of a standardised, consensus-based scoring system.

Authors:  Maria-Antonietta D'Agostino; Lene Terslev; Philippe Aegerter; Marina Backhaus; Peter Balint; George A Bruyn; Emilio Filippucci; Walter Grassi; Annamaria Iagnocco; Sandrine Jousse-Joulin; David Kane; Esperanza Naredo; Wolfgang Schmidt; Marcin Szkudlarek; Philip G Conaghan; Richard J Wakefield
Journal:  RMD Open       Date:  2017-07-11

9.  The DAS28-ESR cutoff value necessary to achieve remission under the new Boolean-based remission criteria in patients receiving tocilizumab.

Authors:  Yasuhiko Hirabayashi; Tomonori Ishii
Journal:  Clin Rheumatol       Date:  2012-10-23       Impact factor: 2.980

Review 10.  Musculoskeletal involvement in sarcoidosis.

Authors:  Akasbi Nessrine; Abourazzak Fatima Zahra; Harzy Taoufik
Journal:  J Bras Pneumol       Date:  2014 Mar-Apr       Impact factor: 2.624

View more
  1 in total

Review 1.  Sarcoidosis with musculoskeletal manifestations: systematic review of non-pharmacological and pharmacological treatments.

Authors:  Geir Smedslund; Annie Martina Kotar; Till Uhlig
Journal:  Rheumatol Int       Date:  2022-08-09       Impact factor: 3.580

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.